合资公司的注册资本为人民币500万元，北京壹伍贰零及北京秀曼科技分别出资人民币255万元及人民币 245万元，分别占注册资本51%及49%。合资公司为公司附属公司，其财务业绩将合并到公司综合财务 报表。 北京秀曼科技由闫凯红先生全资实益拥有。北京秀曼科技主要从事管理谘询及销售业务(含金属产品销 售)。 天机控股(01520)发布公告，于2026年1月29日，公司全资附属公司北京壹伍贰零科技有限公司(北京壹伍 贰零)与北京秀曼科技有限公司(北京秀曼科技)签订了投资合同。根据投资合同，北京壹伍贰零拟与北京 秀曼科技共同出资在中国成都市组建一家合资公司"成都天和鑫睿贵金属有限公司"，拟开拓黄金相关业 务，以黄金为载体融合金融、体育、艺术与跨境贸易多维领域的发展。 集团一直积极寻求扩展其现有的业务，并拥有丰富的AI及Web3技术，以打造覆盖体育、文旅、娱乐及 其他领域的智慧新消费生态。黄金业务核心优势显著，以创新模式打破传统边界，将足金产品与体育、 艺术元素深度融合，同时联动金融服务打造多元生态。这一布局不仅有效提升传统消费业务的客单价， 更实现了黄金金融属性与消费属性的高效叠加、双向赋能，凸显出属性融合带来的综合竞 ...

合资公司的注册资本为人民币500万元，北京壹伍贰零及北京秀曼科技分别出资人民币255万元及人民币 245万元，分别占注册资本51%及49%。合资公司为公司附属公司，其财务业绩将合并到公司综合财务 报表。 集团一直积极寻求扩展其现有的业务，并拥有丰富的AI及Web3技术，以打造覆盖体育、文旅、娱乐及 其他领域的智慧新消费生态。黄金业务核心优势显著，以创新模式打破传统边界，将足金产品与体育、 艺术元素深度融合，同时联动金融服务打造多元生态。这一布局不仅有效提升传统消费业务的客单价， 更实现了黄金金融属性与消费属性的高效叠加、双向赋能，凸显出属性融合带来的综合竞争优势。过去 一年此类商品成交额大幅增长，带动"小金片"与联名饰品成为消费新潮。董事会相信，成立合资公司拓 展黄金业务品类能够使集团进一步拓展其于IP领域的业务至黄金产业，有助开拓新收入来源，并为公司 股东带来回报。 智通财经APP讯，天机控股(01520)发布公告，于2026年1月29日，公司全资附属公司北京壹伍贰零科技 有限公司(北京壹伍贰零)与北京秀曼科技有限公司(北京秀曼科技)签订了投资合同。根据投资合同，北 京壹伍贰零拟与北京秀曼科技共同出资在中国 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不因本公告全部 或部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Virtual Mind Holding Company Limited （於開曼群島註冊成立之有限公司） （股份代號：1520） 自願公告 成立合資公司的投資合同 本公告由天機控股有限公司（「 本公司 」，連同其附屬公司，統稱「 本 集 團」）董事（「董事」）會（「董事會」）自願刊發。 董事會欣然宣佈，於二零二六年一月二十九日，本公司全資附屬公司北京壹伍 貳零科技有限公司（「北京壹伍貳零」）與北京秀曼科技有限公司（「北京秀 曼科技」）簽訂了投資合同（「投資合同」）。根據投資合同，北京壹伍貳零 擬與北京秀曼科技共同出資在中華人民共和國（「中國」）成都市組建一家合 資公司「成都天和鑫睿貴金屬有限公司」（「合資公司」），擬開拓黃金相關 業務，以黃金為載體融合金融、體育、藝術與跨境貿易多維領域的發展（「合 資公司業務」）。 合資公司的註冊資本為人民幣 500 萬元，北京壹伍貳零及北京秀曼科技分別出資 人民幣 255 ...

Investment Rating - The report does not explicitly provide an investment rating for the gynecological drug industry in China. Core Insights - The biopharmaceutical industry in China is experiencing structural optimization, valuation recovery, and confidence rebuilding, particularly in the Hong Kong market, where the 18A system supports enterprise value discovery [2][3]. - Gynecological drug companies are characterized by specialized positioning and differentiated competition, focusing on areas such as traditional Chinese medicine, innovative treatments for gynecological tumors, and hormone drugs, showcasing strong professional images and commercialization capabilities [2][3]. Summary by Sections Capital Market Performance of China's Biopharmaceutical Sector - The A-share market has shifted from a focus on scale to sustainable development, while the Hong Kong market has attracted international capital through the 18A system, leading to a gradual rebuilding of long-term confidence in the biopharmaceutical sector [3][25]. - The A-share biopharmaceutical sector has seen a total fundraising amount of 787 billion yuan from January to October 2025, with a peak of 2,451 billion yuan in 2021, indicating a transition from a capital overheating phase to a rational development phase [13][18]. - In the Hong Kong market, the total fundraising amount reached 789 billion HKD from January to October 2025, with a peak of 1,833 billion HKD in 2020, reflecting a significant improvement in the financing environment [27][28]. Market Position Assessment of Chinese Gynecological Drug Companies - The competitive landscape of gynecological drug companies is marked by a focus on specialized fields such as innovative gynecological tumor drugs and hormone treatments, with companies establishing differentiated competitive advantages [40]. - Qianjin Pharmaceutical is recognized as a leading player in the gynecological drug market, with a strong market presence in oral gynecological inflammation traditional Chinese medicine [40]. - Heng Rui Pharmaceutical is noted for its robust pipeline in gynecological tumor treatments, with eight drugs in development as of 2024 [40]. - Xianju Pharmaceutical specializes in hormone treatments, with a focus on steroid drugs, establishing a strong professional image in the gynecological field [40]. Introduction to Representative Listed Chinese Gynecological Drug Companies - Qianjin Pharmaceutical has a significant market share of 25.8% in oral gynecological inflammation traditional Chinese medicine, demonstrating strong sales performance even in challenging market conditions [45]. - Heng Rui Pharmaceutical's research and development pipeline includes multiple innovative treatments for gynecological tumors, indicating a solid commitment to this therapeutic area [52][53]. - Xianju Pharmaceutical leverages its expertise in steroid drugs to maintain a competitive edge in the gynecological drug market, with a focus on cost-effective production and high-quality formulations [58][61].

证券代码：600129 证券简称：太极集团 公告编号：2025-085 重庆太极实业（集团）股份有限公司 关于公司 2025 年第三季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所上市公司自律监管指引第 3 号——行业信息披露》之《第 六号—医药制造》的相关规定，现将公司 2025 年第三季度主要经营数据披露如下： 一、报告期内分行业经营数据 二、报告期内工业主要品种按治疗领域划分经营数据 单位：万元 产品分类 主营业务收入 主营业务成本 毛利率 (%) 营业收入比 上年同期增 减（%） 营业成本比 上年同期增 减（%） 毛利率同 比增长百 分点 消化及代谢用药[注 1] 129,916 74,730 42.48 -26.57 3.42 -16.68 呼吸系统用药[注 2] 115,690 61,450 46.88 -38.34 -12.45 -15.71 神经系统用药 44,507 13,947 68.66 -12.64 14.93 -7.52 大健康产品 36,402 24,52 ...

Core Viewpoint - The company, Chongqing Taiji Industrial (Group) Co., Ltd., reported a significant decline in its main business revenue and profit margins for the first half of 2025, indicating challenges in various segments of its operations [1][2]. Summary by Category 1. Main Business Revenue and Costs - The total main business revenue for the first half of 2025 was 559,588.74 million RMB, a decrease of 27.61% compared to the previous year [1][2]. - The main business cost was 405,416.86 million RMB, which saw a slight decrease of 1.48% [1][2]. - The overall gross margin was reported at 27.55%, down by 19.21 percentage points year-on-year [1][2]. 2. Segment Performance - **Pharmaceutical Industry**: Revenue was 284,234.75 million RMB, with a gross margin of 42.44%, down 20.46% year-on-year. The cost was 507,878.28 million RMB, reflecting a significant decline in profitability [1]. - **Pharmaceutical Commerce**: Revenue reached 337,213.55 million RMB, with a gross margin of 8.45%, down 0.33%. The cost was 374,145.79 million RMB, indicating a decrease of 9.87% [1]. - **Traditional Chinese Medicine Resources**: Revenue was 49,274.89 million RMB, with a gross margin of 8.51%, showing a slight increase of 0.74%. The cost was 49,005.69 million RMB [1]. - **Health and International Services**: Revenue dropped to 9,514.72 million RMB, with a gross margin of 8.47%, down 0.71%. The cost was 26,542.95 million RMB, reflecting a 64.15% decrease [1]. - **Other Services**: Revenue was 68.42 million RMB, with a gross margin of 66.63%, down 16.17%. The cost was 189.81 million RMB, a decrease of 63.95% [1]. 3. Regional Performance - **Southwest Region**: Revenue was 379,714.39 million RMB, with a gross margin of 20.73%, down 8.58% [2]. - **East China**: Revenue was 87,061.98 million RMB, with a gross margin of 40.94%, down 46.85% [2]. - **South China**: Revenue was 28,509.92 million RMB, with a gross margin of 38.09%, down 56.80% [2]. - **North China**: Revenue was 24,147.85 million RMB, with a gross margin of 56.99%, down 57.66% [2]. - **Central China**: Revenue was 19,341.36 million RMB, with a gross margin of 37.22%, down 47.85% [2]. - **Northwest Region**: Revenue was 11,126.22 million RMB, with a gross margin of 38.00%, down 45.33% [2]. - **Northeast Region**: Revenue was 9,317.72 million RMB, with a gross margin of 38.49%, down 27.12% [2]. - **Overseas**: Revenue was 369.30 million RMB, with a gross margin of 49.63%, down 34.18% [2].

[注 1] 呼吸系统用药的营业收入较上年同期减少 44.69%，主要系本报告 期急支糖浆、鼻窦炎口服液、散列通等销售额减少所致。 证券代码：600129 证券简称：太极集团 公告编号：2025-063 重庆太极实业（集团）股份有限公司 关于公司 2025 年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所上市公司自律监管指引第 3 号——行业信息披露》 之《第六号—医药制造》的相关规定，现将公司 2025 年半年度主要经营数据 披露如下： | | | | | | | | | 单位：万元 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 行业 | 主营业务收入 2025 年 | 2024 年 | 增长率% | 主营业务成本 2025 年 | 2024 年 | 增长率% | 毛利率% 2025 年 | 2024 年 | 同比增长 百分点 | | | 1-6 月 | 1-6 月 | | 1-6 月 | ...